Supplement is a category, not a level of evidence
A supplement can contain an essential nutrient with a well-established indication, a botanical with uncertain benefit, a concentrated ingredient that interacts with medicines or a multi-ingredient blend that has never been tested as sold. The right question is not whether supplements work. It is whether this product, dose and formulation improves a defined outcome for this person at this life stage, with acceptable risk.
In the United States, FDA does not approve supplements for safety and effectiveness before sale; companies are responsible for compliance and oversight is largely post-market [4]. Rules differ internationally. An ingredient panel is not proof that a product prevents disease, uses an optimal dose or improves the advertised outcome.
- Name the intended outcome before choosing a product.
- Separate evidence for an ingredient from evidence for the exact finished product.
- Check regulation and quality requirements in the country of purchase.
Preconception folic acid is a clear evidence-based use
The USPSTF recommends that all people planning or capable of pregnancy take 0.4 to 0.8 mg, or 400 to 800 µg, of folic acid daily [1]. The critical period begins at least 1 month before conception and continues through the first 2 to 3 months of pregnancy because neural-tube closure occurs early, often before pregnancy is recognised. This recommendation is for average-risk people and should be delivered alongside food, medication and health review rather than as a substitute for preconception care.
Higher-dose folic acid is not simply better. People with a previous neural-tube-defect-affected pregnancy or certain medical conditions or medicines need individual guidance because the standard USPSTF recommendation does not cover those high-risk situations [1]. A clinician can also check whether multiple products duplicate folate or other nutrients and review medicines that affect folate metabolism.
- Start before pregnancy is expected, not after the first prenatal visit.
- Add up folic acid across multivitamins, prenatal products and single-ingredient tablets.
- Seek an individual plan for prior neural tube defect, malabsorption or interacting medicines.
Pregnancy needs adequacy without automatic excess
WHO recommends 30 to 60 mg elemental iron and 400 µg folic acid daily during pregnancy to reduce several maternal and newborn risks [2]. Local policies vary with diet, fortification, anaemia prevalence and test results. NIH advises assessing diet and supplement use because prenatal products do not necessarily provide every nutrient appropriately [3].
More is not always safer. NIH states that excessive preformed vitamin A, unlike beta-carotene, can cause congenital birth defects, and lists an upper intake level of 3,000 µg retinol activity equivalents per day for adults during pregnancy [3][8]. Iron can also cause gastrointestinal adverse effects, and the balance differs for iron deficiency and iron-replete states. A medication and supplement review should include fortified foods and all overlapping products.
- Choose a plan that reflects local guidance, diet, clinical history and laboratory evidence.
- Check the form as well as the amount of vitamin A.
- Do not stack prenatal, hair, energy and immune products without calculating totals.
Midlife symptom claims often outrun the evidence
Many products are marketed for hot flashes, sleep, mood, weight, libido or healthy ageing. The Menopause Society's 2023 evidence review did not recommend supplements and herbal remedies for vasomotor symptoms because evidence was insufficient or inconsistent, while it did recommend several behavioural and prescription options with stronger support [5]. This does not mean every nutrient is irrelevant. A documented deficiency, limited intake or specific bone-health plan is a different clinical question from using a blend to treat hot flashes.
Botanical species, extraction methods, doses and combinations may not be interchangeable, and long-term safety data can be sparse. A short-term symptom score is not proof of cardiovascular, cognitive or longevity benefit. Midlife care should identify the symptom and medical context before comparing treatments on evidence, risk, cost and preference.
- Ask whether evidence addresses the exact symptom and formulation.
- Do not infer disease prevention from a change in a biomarker alone.
- Review whether a proven therapy is being delayed by an unproven product.
Interactions can involve medicines, surgery and laboratory tests
St John's wort can weaken the effects of many medicines, including birth-control pills, some antidepressants, transplant medicines, HIV drugs, cancer treatments and warfarin. Combining it with medicines that affect serotonin can also produce serious serotonin-related adverse effects, and pregnancy safety is uncertain [7]. This is why a complete medication list must include teas, powders, gummies and botanicals, not only products that a person thinks of as medicine.
Biotin, common in hair, skin and nail products and some multivitamins, can interfere with certain laboratory tests and cause falsely high or falsely low results. FDA remains concerned about clinically important interference, including some troponin assays [6]. A laboratory or clinician should advise whether a product needs to be stopped and for how long, because assay sensitivity and dose differ. People should not improvise a stopping interval from social media.
- Bring product photos or containers to medication reviews.
- Tell the surgical, fertility, pregnancy and laboratory teams about every supplement.
- Check for duplicated ingredients and known medicine interactions before purchase.
A safer supplement plan has a stop rule
A responsible plan records the product, manufacturer, lot where relevant, ingredient form, daily dose, purpose, start date and review date. FDA and NCCIH advise discussing supplements with clinicians because adverse effects and medicine interactions may be clinically important [4][7]. The plan defines an outcome that matters, such as correcting a measured deficiency or meeting a guideline-based preconception need. It also defines what will trigger stopping: pregnancy, an adverse effect, a medication change, surgery, an abnormal laboratory result, no meaningful benefit by the review date or new evidence of harm.
Quality verification can assess identity and contamination but does not prove benefit. Marketing terms are not outcome evidence. A non-judgmental shared review supports disclosure, preserves proven uses, removes duplication and helps prevent disruption of contraception, pregnancy care, cancer treatment or diagnostic testing.
- Use one shared list for prescriptions, over-the-counter medicines and supplements.
- Set a review date and an explicit stop rule.
- Report serious adverse events through the relevant national safety system.
What the evidence cannot yet answer
- Supplement formulations, doses and quality vary, so evidence for one preparation may not apply to another product with the same headline ingredient.
- Pregnancy and lactation safety data are limited for many botanicals and multi-ingredient blends.
- Regulatory frameworks and population supplementation recommendations differ by country, diet, food fortification and deficiency prevalence.
Questions worth taking into care
- What exact outcome is this supplement intended to improve, and how strong is the evidence?
- Does the studied formulation and dose match the product in my hand?
- Could it interact with contraception, pregnancy medicines, cancer treatment, anticoagulants or laboratory tests?
- Am I duplicating nutrients across food, fortified products and several supplements?
- When will benefit and harm be reviewed, and what is the stop rule?
Source record
Evidence used in this review
Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.
- [1]Folic Acid Supplementation to Prevent Neural Tube Defects: Clinician Summary
U.S. Preventive Services Task Force · 2023
- [2]Daily Iron and Folic Acid Supplementation During Pregnancy
World Health Organization · 2024
- [3]Dietary Supplements and Life Stages: Pregnancy
National Institutes of Health Office of Dietary Supplements · 2025
- [4]FDA 101: Dietary Supplements
U.S. Food and Drug Administration · 2025
- [5]The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society
The Menopause Society · 2023
- [6]Biotin Interference with Troponin Lab Tests
U.S. Food and Drug Administration · 2021
- [7]St. John's Wort: Usefulness and Safety
National Center for Complementary and Integrative Health · 2026
- [8]Vitamin A and Carotenoids: Health Professional Fact Sheet
National Institutes of Health Office of Dietary Supplements · 2025
This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.